Multiprotein genetic vaccine in the SIV‐Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection
- 1 August 2007
- journal article
- research article
- Published by Wiley in Journal of Medical Primatology
- Vol. 36 (4-5) , 180-194
- https://doi.org/10.1111/j.1600-0684.2007.00236.x
Abstract
Background Vaccine combining structural and regulatory proteins is an emerging approach to develop an HIV/AIDS vaccine and therefore, the immunogenicity and efficacy of two regimens of immunization combining structural (Gag/Pol, Env) and regulatory (Rev, Tat, Nef) Simian immunodeficiency virus (SIV) proteins were compared in cynomolgus monkeys. Methods Monkeys were immunized with Modified Vaccine Ankara vector (MVA‐J5) (protocol 1) or with DNA, Semliki forest virus and MVA vectors (DNA/SFV/MVA) (protocol 2). At week 32, all monkeys were challenge intravenously (protocol 1) or intrarectally (protocol 2) with 50 MID50 of SIVmac251. Humoral, proliferative responses and in particular in protocol 2, the frequency of IFN‐γ producing cells, were measured in all monkeys before and after the challenge. Results Both vaccine regimens elicited humoral and proliferative responses but failed to induce neutralizing antibodies. Upon intravenous challenge, two out of three MVA‐J5 vaccinated monkeys exhibited a long‐term control of the viral replication whereas DNA/SFV/MVA vaccine abrogated the virus replication up to undetectable level in three out of four vaccinated monkeys. A major contribution to this vaccine effect appeared to be the IFN‐γ/ELISPOT responses to vaccine antigens (Gag, Rev Tat and Nef). Conclusions These results, indicate that multiprotein heterologous prime‐boost vaccination can induce a robust vaccine‐induced immunity able to abrogate virus replication.Keywords
This publication has 52 references indexed in Scilit:
- Does preserving memory correlate with surviving HIV?Trends in Microbiology, 2007
- The Absence of Anti‐Tat Antibodies Is Associated with Risk of Disease Progression in HIV‐2 InfectionThe Journal of Infectious Diseases, 2006
- Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged MonkeysScience, 2006
- Changes in Soluble Factor-Mediated CD8+Cell-Derived Antiviral Activity in Cynomolgus Macaques Infected with Simian Immunodeficiency Virus SIVmac251: Relationship to Biological Markers of ProgressionJournal of Virology, 2006
- CD8 + Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency VirusJournal of Virology, 2005
- The Presence of Anti‐Tat Antibodies Is Predictive of Long‐Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIV‐1 SeroconvertersThe Journal of Infectious Diseases, 2005
- Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particlesVaccine, 2004
- Contribution of Human α-Defensin 1, 2, and 3 to the Anti-HIV-1 Activity of CD8 Antiviral FactorScience, 2002
- Live attenuated SIV—a model of a vaccine for AIDSImmunology Letters, 1999
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995